Search research articles
Contact Us
Filters
Showing results (251-260 of 317) with videos related to
Page
of 32
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1992
Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography
F M Muggia, E LePoidevin, S Jeffers, et al.
Gynecologic Oncology
|
August 1, 1997
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin)
F M Muggia, S Jeffers, L Muderspach, et al.
Cancer Treatment Reports
|
April 1, 1984
Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancer
M D Green, J S Speyer, J C Bottino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 1998
Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity
T W Synold, E M Newman, M Carroll, et al.
Gynecologic Oncology
|
August 1, 1993
Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens
F M Muggia, S Groshen, C Russell, et al.
Investigational New Drugs
|
August 1, 1990
Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer
M D Green, J L Speyer, J C Wernz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 1996
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil
F M Muggia, X Wu, D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies
B Uziely, S Jeffers, R Isacson, et al.
Cancer
|
October 1, 1972
Clinical study with bleomycin: tolerance to twice weekly dosage
T Onuma, O S Selawry, J F Holland, et al.
Anti-Cancer Drugs
|
June 1, 1992
High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers
F M Muggia, T D Brown, P J Goodman, et al.
Page
of 32
Search research articles
Search
Showing results (251-260 of 317) with videos related to
Sort By:
Page
of 32
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 1992
Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography
F M Muggia, E LePoidevin, S Jeffers, et al.
Gynecologic Oncology
|
August 1, 1997
Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin)
F M Muggia, S Jeffers, L Muderspach, et al.
Cancer Treatment Reports
|
April 1, 1984
Phase I-II study of the continuous infusion of doxorubicin in the treatment of non-small cell lung cancer
M D Green, J S Speyer, J C Bottino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 1998
Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity
T W Synold, E M Newman, M Carroll, et al.
Gynecologic Oncology
|
August 1, 1993
Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens
F M Muggia, S Groshen, C Russell, et al.
Investigational New Drugs
|
August 1, 1990
Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer
M D Green, J L Speyer, J C Wernz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 1996
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil
F M Muggia, X Wu, D Spicer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies
B Uziely, S Jeffers, R Isacson, et al.
Cancer
|
October 1, 1972
Clinical study with bleomycin: tolerance to twice weekly dosage
T Onuma, O S Selawry, J F Holland, et al.
Anti-Cancer Drugs
|
June 1, 1992
High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers
F M Muggia, T D Brown, P J Goodman, et al.
Page
of 32